• TechCrunch
• CrunchBase
• More
  • TechCrunch Europe
  • TechCrunch France
  • TechCrunch Japan

Charter Life Sciences

edit

CHARTER LIFE SCIENCES (“CLS”) is a clinical stage life sciences venture capital investor. CLS makes initial portfolio company investments in life sciences companies that are seeking capital to obtain initial clinical proof-of-efficacy of their products (see Investment Criteria), and they continue to support their successful portfolio companies with follow on investments until they are acquired or go public.

Milestones

edit

• 
  Charter Life Sciences invested in Xlumena. (4/29/11)
  Posted 4/29/11 at 6:16pm via pehub.com
• 
  Charter Life Sciences invested in Great Lakes Pharmaceuticals. (8/23/10)
  Posted 8/23/10 at 7:30am via onbiovc.com
• 
  Charter Life Sciences invested in Corepair. (2/11/08)
  Posted 6/8/10 at 11:38am via sec.gov
• 
  Charter Life Sciences invested in Corepair. (4/30/10)
  Posted 6/8/10 at 11:38am via sec.gov
• 
  Charter Life Sciences invested in Inviragen. (10/6/09)
  Posted 10/8/09 at 2:22am via inviragen.com
• 
  Charter Life Sciences invested in APT Pharmaceuticals. (9/30/08)
  Posted 7/15/09 at 8:30pm via aptbio.com

Investments

Videos

Sources

1. Xlumena Closes $7M Series B (pehub.com) [edit]
2. Great Lakes Pharmaceuticals, Inc.: Series B $3.1M (onbiovc.com) [edit]
3. SEC filing (sec.gov) [edit]
4. Inviragen Completes $15 million Series A Financing (inviragen.com) [edit]
5. APT Pharmaceuticals Secures $32 Million in Series B Financing (aptbio.com) [edit]
6. SEC filing (sec.gov) [edit]